Patents by Inventor Martin Huelsmeyer
Martin Huelsmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180141988Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: May 18, 2016Publication date: May 24, 2018Applicant: Pieris Pharmaceuticals GmbHInventors: Marlon HINNER, Andrea ALLERSDORFER, Rachida Siham BEL AIBA, Michaela ALOE, Alexander WIEDENMANN, Gabriele MATSCHINER, Martin HUELSMEYER
-
Publication number: 20180086799Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: November 16, 2017Publication date: March 29, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20180037618Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. acruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: October 5, 2017Publication date: February 8, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20180037619Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: October 6, 2017Publication date: February 8, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Patent number: 9884898Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: GrantFiled: May 23, 2017Date of Patent: February 6, 2018Assignee: SANOFIInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Bernhard Calandra, Astrid Rey, Nathalie Karst, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20180030101Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: October 6, 2017Publication date: February 1, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20170369542Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: July 7, 2017Publication date: December 28, 2017Applicant: PIERIS PHARMACEUTICALS GMBHInventors: Stefan TRENTMANN, Gabriele MATSCHINER, Arne SKERRA, Andreas HOHLBAUM, Martin HUELSMEYER, Hendrik GILLE, Hans-Juergen CHRISTIAN, Kristian JENSEN, Rachida Siham BEL AIBA
-
Publication number: 20170267734Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: May 23, 2017Publication date: September 21, 2017Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Patent number: 9751920Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: December 14, 2015Date of Patent: September 5, 2017Assignee: PIERIS PHARMACEUTICALS GMBHInventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
-
Publication number: 20170114109Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.Type: ApplicationFiled: December 15, 2016Publication date: April 27, 2017Applicant: Pieris Pharmaceuticals GmbHInventors: ARNE SKERRA, Michaela GEBAUER, Dominik HINZ, Sabine RAUTH, Gabriele MATSCHINER, Martin HUELSMEYER
-
Publication number: 20170029477Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: ApplicationFiled: July 6, 2016Publication date: February 2, 2017Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Patent number: 9549968Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.Type: GrantFiled: December 7, 2010Date of Patent: January 24, 2017Assignee: Pieris Pharmaceuticals GmbHInventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
-
Publication number: 20160256525Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: December 28, 2015Publication date: September 8, 2016Applicant: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Publication number: 20160200780Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: December 14, 2015Publication date: July 14, 2016Applicant: PIERIS AGInventors: GABRIELE MATSCHINER, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, STEFAN TRENTMANN
-
Patent number: 9221887Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: September 14, 2012Date of Patent: December 29, 2015Assignee: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 9212208Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: January 29, 2009Date of Patent: December 15, 2015Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
-
Publication number: 20150344538Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.Type: ApplicationFiled: November 20, 2013Publication date: December 3, 2015Applicant: PIERIS AGInventors: Marlon HINNER, Laurent AUDOLY, Martin HUELSMEYER, Kristian JENSEN, Gabriele MATSCHINER, Shane OLWILL, Alexander WIEDENMANN, Andrea ALLERSDORFER
-
Publication number: 20150291675Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: May 6, 2015Publication date: October 15, 2015Applicant: PIERIS AGInventors: STEFAN TRENTMANN, GABRIELE MATSCHINER, ARNE SKERRA, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, HENDRIK GILLE, HANS-JUERGEN CHRISTIAN, KRISTIAN JENSEN, RACHIDA SIHAM BEL AIBA
-
Patent number: 9051382Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: GrantFiled: August 16, 2011Date of Patent: June 9, 2015Assignee: PIERIS AGInventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba
-
Publication number: 20130244955Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: August 16, 2011Publication date: September 19, 2013Inventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba